KardiaMobile for detecting atrial fibrillation

of these can be interpreted by a clinician. Cost evidence Published cost evidence includes 2 UK studies representing NHS costs 3.8 Three published studies reported the economic impact of KardiaMobile: • a cost-effectiveness analysis done alongside a UK RCT compared the cost per symptomatic rhythm diagnosis using KardiaMobile in addition to standard care with standard care alone (Reed et al. 2019) • a UK budget impact analysis (York Health Economics Consortium et al. 2018) • a US single-arm study estimated the cost saving using data from a patient survey (Praus et al. 2021). All studies reported that KardiaMobile was cost saving. Two studies reported that the main driver for the saving was a reduction in healthcare appointments. The company presented a cost model showing that monitoring with KardiaMobile is cost saving 3.9 The company developed a de novo model comparing KardiaMobile with Holter monitoring and the Zio patch. The model included people aged 64 and over with known or suspected AF who were referred for ambulatory ECG monitoring in a secondary care setting. The model assessed the costs associated with diagnosing and managing AF. Overall, the company's base case showed that using KardiaMobile could save between £320 and £380 per
